Science, Technology And Society Practice Test

Balancing incentives for innovation with the need for affordable medicines relies on mechanisms that preserve patent protection while opening doors to affordable options when needed. Compulsory licensing is a policy tool that allows a government to authorize a third party to produce a patented medicine without the patent holder’s consent, usually with negotiated royalties paid to the patent owner. This approach leverages international flexibilities designed to protect public health, ensuring that access to essential medicines is possible during shortages or health emergencies while maintaining the overall incentive structure for research and development through market-based compensation. It directly improves access by enabling affordable, locally produced generics without permanently erasing IP rights. In contrast, extending patent terms or data exclusivity lengthens monopolies and raises prices, further delaying generic competition, which is why they’re not suitable for balancing IP incentives with access.